DPP4 and dermatomyositis: Concurrently, DPP-4/CD26 expression in the patient's skin and skeletal muscle was observed.<h4>Interventions</h4>The patient was treated with begelomab, a murine immunoglobulin G2b monoclonal antibody against DPP-4/CD26.<h4>Outcomes</h4>Dysphagia, skin lesions and intestinal vasculitis resolved and the patient experienced a significant improvement of his quality of life.<h4>Conclusion</h4>Blockade of DPP-4/CD26, which is expressed on T cells and mediates T cell activation and function, is safe and might be effective in patients with refractory DM.